These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19460157)

  • 21. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
    Tokayer A; Carsons SE; Chokshi B; Santiago-Schwarz F
    J Rheumatol; 2002 Mar; 29(3):454-61. PubMed ID: 11908556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.
    Chen DY; Chen YM; Chen HH; Hsieh CW; Lin CC; Lan JL
    Arthritis Res Ther; 2011 Jul; 13(4):R126. PubMed ID: 21801431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cytokines and anti-cytokine therapy in rheumatoid arthritis].
    Lorenz HM; Kalden JR
    Internist (Berl); 2001 Jan; 42(1):55-6, 59-63. PubMed ID: 11271621
    [No Abstract]   [Full Text] [Related]  

  • 26. Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy.
    McGeough CM; Berrar D; Wright G; Mathews C; Gilmore P; Cunningham RT; Bjourson AJ
    Rheumatol Int; 2012 Jun; 32(6):1647-53. PubMed ID: 21373785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
    Jani M; Chinoy H; Warren RB; Griffiths CE; Plant D; Fu B; Morgan AW; Wilson AG; Isaacs JD; Hyrich K; Barton A;
    Arthritis Rheumatol; 2015 May; 67(8):2011-9. PubMed ID: 26109489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.
    Mavragani CP; La DT; Stohl W; Crow MK
    Arthritis Rheum; 2010 Feb; 62(2):392-401. PubMed ID: 20112385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Creutzfeldt-Jakob disease in a patient treated by etanercept for rheumatoid arthritis (RA): just a coincidence?
    Soubrier M; Haïk S; Hauw JJ; Corvol JC; Lyon-Caen O; Dougados M
    Joint Bone Spine; 2010 Mar; 77(2):174-5. PubMed ID: 20097590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.
    Naredo E; Möller I; Cruz A; Carmona L; Garrido J
    Arthritis Rheum; 2008 Aug; 58(8):2248-56. PubMed ID: 18668537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.
    Kobie JJ; Zheng B; Bryk P; Barnes M; Ritchlin CT; Tabechian DA; Anandarajah AP; Looney RJ; Thiele RG; Anolik JH; Coca A; Wei C; Rosenberg AF; Feng C; Treanor JJ; Lee FE; Sanz I
    Arthritis Res Ther; 2011; 13(6):R209. PubMed ID: 22177419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis.
    Tikiz H; Arslan O; Pirildar T; Tikiz C; Bayindir P
    Anadolu Kardiyol Derg; 2010 Apr; 10(2):98-103. PubMed ID: 20382605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial.
    Curtis JR; Yang S; Chen L; Park GS; Bitman B; Wang B; Navarro-Millan I; Kavanaugh A
    Ann Rheum Dis; 2012 Feb; 71(2):206-12. PubMed ID: 21998118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
    Segal B; Rhodus NL; Patel K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.
    Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z
    Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
    Catrina AI; Lampa J; Ernestam S; af Klint E; Bratt J; Klareskog L; Ulfgren AK
    Rheumatology (Oxford); 2002 May; 41(5):484-9. PubMed ID: 12011369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.